TherapeuticsMD, Inc. (NASDAQ:TXMD) saw a large increase in short interest in the month of December. As of December 29th, there was short interest totalling 55,882,896 shares, an increase of 4.4% from the December 15th total of 53,505,064 shares. Based on an average daily volume of 2,720,761 shares, the days-to-cover ratio is presently 20.5 days. Approximately 32.1% of the shares of the company are sold short.
A number of equities research analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $28.00 target price on shares of TherapeuticsMD in a report on Sunday, January 7th. BidaskClub cut shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Wednesday, September 27th. Zacks Investment Research cut shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Friday, January 12th. Noble Financial reissued a “buy” rating on shares of TherapeuticsMD in a report on Friday, December 29th. Finally, Jefferies Group reissued a “buy” rating and issued a $15.00 price target on shares of TherapeuticsMD in a report on Tuesday, September 26th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. TherapeuticsMD currently has a consensus rating of “Buy” and an average target price of $14.50.
In other news, Director Tommy G. Thompson bought 5,000 shares of the company’s stock in a transaction dated Friday, December 8th. The shares were bought at an average cost of $6.21 per share, with a total value of $31,050.00. Following the acquisition, the director now owns 3,555 shares in the company, valued at $22,076.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 23.92% of the stock is currently owned by corporate insiders.
TherapeuticsMD (NASDAQ TXMD) opened at $6.21 on Wednesday. The firm has a market cap of $1,340.00, a PE ratio of -15.92 and a beta of 1.06. TherapeuticsMD has a fifty-two week low of $3.50 and a fifty-two week high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Monday, November 6th. The company reported ($0.07) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. The firm had revenue of $4.42 million for the quarter, compared to analysts’ expectations of $5.36 million. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The business’s revenue was down 19.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.13) EPS. equities analysts anticipate that TherapeuticsMD will post -0.37 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “TherapeuticsMD, Inc. (TXMD) Short Interest Up 4.4% in December” was originally reported by BBNS and is the sole property of of BBNS. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://baseballnewssource.com/markets/therapeuticsmd-inc-txmd-short-interest-up-4-4-in-december/1840836.html.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.